Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
β Scribed by Pamela A. Trail; Dalton H. King; Gene M. Dubowchik
- Publisher
- Springer-Verlag
- Year
- 2003
- Tongue
- English
- Weight
- 238 KB
- Volume
- 52
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Monoclonal antibodies directed to tumor-associated antigens have been chemically conjugated to drugs with different mechanisms of action and different levels of potency. Monoclonal-antibody-directed drug delivery has the potential to both improve efficacy and reduce systemic toxicity. Several immuno
Monoclonal antibodies (MAbs) to ras, sis, erb-B, src, myb and myc oncoproteins were evaluated for their potential to target anti-cancer drugs to malignant cells. Each antibody was tested for reactivity against both fixed and viable cultured human tumour cells by immunofluorexence, and all reacted ag